$TGTX
TG THERAPEUTICS, INC. Stock $tgtx

$tgtx Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000143774924006144 Filed on February 29, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$63.47M	$43.97M	$233.7M
YoY Change	713.46%	54863.75%	8290.02%
Cost Of Revenue	$5.441M	$7.855M	$14.13M
YoY Change	534.89%	261733.33%	5232.45%
Gross Profit	$58.03M	$36.12M	$219.5M
YoY Change	735.49%	46803.9%	8611.55%
Gross Profit Margin	91.43%	82.14%	93.95%
Selling, General & Admin	$34.58M	$31.15M	$122.7M
YoY Change	23.2%	38.43%	75.28%
% of Gross Profit	59.59%	86.26%	55.89%
Research & Development	$32.72M	$17.45M	$76.19M
YoY Change	106.19%	-41.12%	-39.22%
% of Gross Profit	56.39%	48.31%	34.71%
Depreciation & Amortization	$29.00K	$38.00K	$211.0K
YoY Change	-57.35%	-47.95%	-30.36%
% of Gross Profit	0.05%	0.11%	0.1%
Operating Expenses	$67.30M	$48.60M	$198.9M
YoY Change	50.25%	-6.79%	1.67%
Operating Profit	-$9.270M	-$12.49M	$20.63M
YoY Change	-74.94%	-76.02%	-110.7%
Interest Expense	$2.288M	-$2.432M	$12.62M
YoY Change	-19.55%	-15.02%	23.79%
% of Operating Profit			61.14%
Other Income/Expense, Net	-$1.408M	$891.0K	-$7.571M
YoY Change	-37.14%	-53.83%	37.75%
Pretax Income	-$10.68M	-$14.03M	$13.06M
YoY Change	-72.78%	-73.53%	-106.59%
Income Tax	$29.00K	$390.0K	$390.0K
% Of Pretax Income			2.99%
Net Earnings	-$10.71M	-$14.42M	$12.67M
YoY Change	-72.71%	-72.8%	-106.39%
Net Earnings / Revenue	-16.87%	-32.79%	5.42%
Basic Earnings Per Share	-$0.07		$0.09
Diluted Earnings Per Share	-$0.07	-$0.10	$0.09
COMMON SHARES
Basic Shares Outstanding	154.4M	151.4M	142.0M
Diluted Shares Outstanding			148.5M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$209.8M	$217.5M	$217.5M
YoY Change	50.16%	34.53%	34.53%
Cash & Equivalents	$75.48M	$92.93M	$92.93M
Short-Term Investments	$134.3M	$124.6M	$124.6M
Other Short-Term Assets	$8.095M	$5.336M	$9.519M
YoY Change	81.58%	126.2%	44.31%
Inventory	$77.72M	$39.82M	$39.82M
Prepaid Expenses
Receivables	$64.98M	$51.09M	$51.09M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$360.6M	$317.9M	$317.9M
YoY Change	95.14%	88.94%	88.94%
LONG-TERM ASSETS
Property, Plant & Equipment	$66.00K	$95.00K	$9.560M
YoY Change	-72.15%	-69.06%	-11.66%
Goodwill	$799.0K	$799.0K
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$1.320M	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Assets	$1.289M	$1.285M	$1.285M
YoY Change	1.02%	0.94%	0.94%
Total Long-Term Assets	$12.74M	$11.64M	$11.64M
YoY Change	1.33%	-53.97%	-53.97%
TOTAL ASSETS
Total Short-Term Assets	$360.6M	$317.9M	$317.9M
Total Long-Term Assets	$12.74M	$11.64M	$11.64M
Total Assets	$373.3M	$329.6M	$329.6M
YoY Change	89.16%	70.27%	70.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$87.27M	$38.47M	$38.47M
YoY Change	52.85%	-8.44%	-8.44%
Accrued Expenses	$4.981M	$13.62M	$13.62M
YoY Change	4.58%	36.0%	36.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$99.68M	$53.72M	$53.72M
YoY Change	58.04%	0.98%	0.98%
LONG-TERM LIABILITIES
Long-Term Debt	$101.3M	$100.1M	$100.1M
YoY Change	5.0%	40.74%	40.74%
Other Long-Term Liabilities	$12.20M	$15.25M	$15.25M
YoY Change	17.96%	43.18%	43.18%
Total Long-Term Liabilities	$101.3M	$100.1M	$115.4M
YoY Change	5.0%	40.74%	41.06%
TOTAL LIABILITIES
Total Short-Term Liabilities	$99.68M	$53.72M	$53.72M
Total Long-Term Liabilities	$101.3M	$100.1M	$115.4M
Total Liabilities	$213.2M	$169.1M	$169.1M
YoY Change	25.48%	25.26%	25.26%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.500B	-$1.514B
YoY Change	-6.25%	-0.83%
Common Stock	$155.0K	$151.0K
YoY Change	4.03%	3.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$200.0K
YoY Change		0.0%
Treasury Stock Shares
Shareholders Equity	$160.1M	$160.5M	$160.5M
YoY Change
Total Liabilities & Shareholders Equity	$373.3M	$329.6M	$329.6M
YoY Change	89.16%	70.27%	70.27%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$10.71M	-$14.42M	$12.67M
YoY Change	-72.71%	-72.8%	-106.39%
Depreciation, Depletion And Amortization	$29.00K	$38.00K	$211.0K
YoY Change	-57.35%	-47.95%	-30.36%
Cash From Operating Activities	-$8.207M	-$13.21M	-$31.41M
YoY Change	-86.3%	-44.66%	-82.17%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$9.255M	-$44.76M	-$50.65M
YoY Change	50.05%	-375.04%	153.27%
Cash From Investing Activities	-$9.255M	-$44.76M	-$50.65M
YoY Change	50.05%	-375.09%	153.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$46.30M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$10.00K	-1.000K	$72.71M
YoY Change	-99.96%	-102.04%	-18694.63%
NET CHANGE
Cash From Operating Activities	-$8.207M	-13.21M	-$31.41M
Cash From Investing Activities	-$9.255M	-44.76M	-$50.65M
Cash From Financing Activities	$10.00K	-1.000K	$72.71M
Net Change In Cash	-$17.45M	-57.97M	-$9.359M
YoY Change	-57.26%	667.56%	-95.24%
FREE CASH FLOW
Cash From Operating Activities	-$8.207M	-$13.21M	-$31.41M
Capital Expenditures		$0.00	$0.00
Free Cash Flow		-$13.21M	-$31.41M
YoY Change		-44.67%	-82.17%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	151465598
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	146426697
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	151424289
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	146385388
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	41309
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	41309
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	20633000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-192839000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-344770000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5044000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4695000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2307000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	13062000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-198335000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-348101000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	390000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	12672000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-198335000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-348101000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.09
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.46
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.63
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.09
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2359000	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.46
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.63
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	6582000	usd
CY2023Q4	tgtx	Amount Of Inventory Net AmountOfInventoryNet	39824000	usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	1-32639
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	36-3898269
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	3020 Carrington Mill Blvd, Suite 475
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Morrisville
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NC
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	27560
CY2023	dei	City Area Code CityAreaCode	212
CY2023	dei	Local Phone Number LocalPhoneNumber	554-4484
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001
CY2023	dei	Trading Symbol TradingSymbol	TGTX
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	3400000000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	154420772
CY2023	dei	Auditor Name AuditorName	KPMG LLP
CY2023	dei	Auditor Location AuditorLocation	New York, NY
CY2023	dei	Auditor Firm AuditorFirmId	185
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	92933000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	102304000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	124575000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	59374000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	51093000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	39823000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	0	usd
CY2023Q4	tgtx	Prepaid Research And Development PrepaidResearchAndDevelopment	4183000	usd
CY2022Q4	tgtx	Prepaid Research And Development PrepaidResearchAndDevelopment	4237000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	5336000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	317943000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	168274000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1285000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1273000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	0	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	12404000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8050000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8888000	usd
CY2023Q4	tgtx	Leasehold Interest LeaseholdInterest	1415000	usd
CY2022Q4	tgtx	Leasehold Interest LeaseholdInterest	1627000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	95000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	307000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	799000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	799000	usd
CY2023Q4	us-gaap	Assets Assets	329587000	usd
CY2022Q4	us-gaap	Assets Assets	193572000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	38471000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	42019000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1631000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1169000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1446000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1581000	usd
CY2023Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	12172000	usd
CY2022Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	8432000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	53720000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	53201000	usd
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	6016000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	305000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	100118000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	71135000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9231000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10344000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	169085000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	134985000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	151000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	146000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1674946000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1585708000	usd
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	234000	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	234000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1514361000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1527033000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	160502000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	58587000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	329587000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	193572000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	233662000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2785000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6689000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14131000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	265000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	790000	usd
CY2023	tgtx	Non Cash Compensation Research And Development Expenses NonCashCompensationResearchAndDevelopmentExpenses	13010000	usd
CY2022	tgtx	Non Cash Compensation Research And Development Expenses NonCashCompensationResearchAndDevelopmentExpenses	13224000	usd
CY2021	tgtx	Non Cash Compensation Research And Development Expenses NonCashCompensationResearchAndDevelopmentExpenses	24047000	usd
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	63182000	usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	112128000	usd
CY2021	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	198532000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	76192000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	125352000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	222579000	usd
CY2023	tgtx	Non Cash Compensation Selling General And Administrative Expenses NonCashCompensationSellingGeneralAndAdministrativeExpenses	24923000	usd
CY2022	tgtx	Non Cash Compensation Selling General And Administrative Expenses NonCashCompensationSellingGeneralAndAdministrativeExpenses	5961000	usd
CY2021	tgtx	Non Cash Compensation Selling General And Administrative Expenses NonCashCompensationSellingGeneralAndAdministrativeExpenses	37227000	usd
CY2023	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	97783000	usd
CY2022	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	64046000	usd
CY2021	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	90863000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	122706000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	70007000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	128090000	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	213029000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	195624000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	351459000	usd
CY2023	us-gaap	Interest Expense InterestExpense	12615000	usd
CY2022	us-gaap	Interest Expense InterestExpense	10191000	usd
CY2021	us-gaap	Interest Expense InterestExpense	5638000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7571000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5496000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3331000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	141955112
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	135411258
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	132222753
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	148508465
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	135411258
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	132222753
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	519350000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	216000	usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2195000	usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	204000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	61274000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-348101000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	237153000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	584000	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	19185000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-198335000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	58587000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1534000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2023	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	595000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	-0	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	40818000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	12672000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	160502000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	12672000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-198335000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-348101000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	37933000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	19185000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	61274000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	211000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	303000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	282000	usd
CY2023	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	2236000	usd
CY2022	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	331000	usd
CY2021	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-517000	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2378000	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1844000	usd
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1080000	usd
CY2023	tgtx	Amortization Of Leasehold Interest AmortizationOfLeaseholdInterest	212000	usd
CY2022	tgtx	Amortization Of Leasehold Interest AmortizationOfLeaseholdInterest	212000	usd
CY2021	tgtx	Amortization Of Leasehold Interest AmortizationOfLeaseholdInterest	212000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1963000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2715000	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1896000	usd
CY2023	tgtx	Change In Fair Value Of Notes Payable ChangeInFairValueOfNotesPayable	-113000	usd
CY2022	tgtx	Change In Fair Value Of Notes Payable ChangeInFairValueOfNotesPayable	116000	usd
CY2021	tgtx	Change In Fair Value Of Notes Payable ChangeInFairValueOfNotesPayable	578000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	36938000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-0	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-0	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	2831000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-8181000	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	8508000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	51093000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1389000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1389000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	192000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-11010000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	15991000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2375000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2332000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2012000	usd
CY2023	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	2675000	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	2277000	usd
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-16146000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	5711000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-152000	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-152000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-31413000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-176170000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-295634000	usd
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	96229000	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	87275000	usd
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	55600000	usd
CY2023	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	146880000	usd
CY2022	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	107274000	usd
CY2021	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	55531000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	401000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-50651000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-20013000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-332000	usd
CY2023	us-gaap	Proceeds From Repayments Of Secured Debt ProceedsFromRepaymentsOfSecuredDebt	0	usd
CY2022	us-gaap	Proceeds From Repayments Of Secured Debt ProceedsFromRepaymentsOfSecuredDebt	-975000	usd
CY2021	us-gaap	Proceeds From Repayments Of Secured Debt ProceedsFromRepaymentsOfSecuredDebt	-30000000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	46296000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2219000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1534000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	584000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	216000	usd
CY2023	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	25000000	usd
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	70000000	usd
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	125000	usd
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	-0	usd
CY2021	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1016000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	72705000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-391000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	41419000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9359000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-196574000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-254547000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	103577000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	300151000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	554698000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	94218000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	103577000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	300151000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	92933000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	102304000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	298887000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	1285000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	1273000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	1264000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94218000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	103577000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	300151000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	8771000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	5445000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	3466000	usd
CY2023	tgtx	Deferred Financing Costs Noncash DeferredFinancingCostsNoncash	1238000	usd
CY2022	tgtx	Deferred Financing Costs Noncash DeferredFinancingCostsNoncash	0	usd
CY2021	tgtx	Deferred Financing Costs Noncash DeferredFinancingCostsNoncash	0	usd
CY2023	tgtx	Warrants Issued With Debt Financing Noncash WarrantsIssuedWithDebtFinancingNoncash	595000	usd
CY2022	tgtx	Warrants Issued With Debt Financing Noncash WarrantsIssuedWithDebtFinancingNoncash	0	usd
CY2021	tgtx	Warrants Issued With Debt Financing Noncash WarrantsIssuedWithDebtFinancingNoncash	0	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1500000000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	217500000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>USE OF ESTIMATES</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the applicable reporting period. On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue, accrued clinical trial expenses and stock-based compensation. Actual results could differ from those estimates. Such differences could be material to the financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
CY2023Q4	us-gaap	Restricted Cash And Investments RestrictedCashAndInvestments	1300000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>CREDIT RISK</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company maintains its cash and cash equivalents and short-term investments with high-credit quality financial institutions. At times, such amounts <em style="font: inherit;"> may </em>exceed federally-insured limits.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
CY2022Q4	tgtx	Prepaid Research And Development PrepaidResearchAndDevelopment	4200000	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13169240
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12650658
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13280608
CY2023	us-gaap	Net Income Loss NetIncomeLoss	12672000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-198335000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-348101000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	141955112
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	135411258
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	132222753
CY2023	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	6553353
CY2021	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	148508465
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	135411258
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	132222753
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.09
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.46
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.63
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.09
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.46
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.63
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	233662000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2785000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6689000	usd
CY2022Q4	us-gaap	Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss	71778000	usd
CY2022Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	0	usd
CY2022Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	1482000	usd
CY2022Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	70296000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	31243000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1999000	usd
CY2023Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	357000	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	357000	usd
CY2022Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	243000	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	243000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	41309
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	200000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	37900000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19200000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	61300000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	37900000	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2526166
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.99
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y1M6D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	115472832	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	52694
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.1
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	5935
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.1
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2467537
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.06
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y11M26D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	29503551	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2975000
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	142409
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.1
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	164443
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.84
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5135685
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.1
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y1M2D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	25064799	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	246156
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.08
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	192500
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	11.3
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4697029
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.98
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y1M6D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	47607209	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2133273
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.6
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y8M19D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	22518984	usd
CY2023Q1	tgtx	Debt Instrument Fee Percentage Of Aggregate Principle Amount DebtInstrumentFeePercentageOfAggregatePrincipleAmount	0.0495	pure
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	95000000	usd
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	70000000	usd
CY2023Q4	tgtx	Long Term Debt Accreted Liability Of Final Payment Fee LongTermDebtAccretedLiabilityOfFinalPaymentFee	10230000	usd
CY2022Q4	tgtx	Long Term Debt Accreted Liability Of Final Payment Fee LongTermDebtAccretedLiabilityOfFinalPaymentFee	6667000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	105230000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	76667000	usd
CY2023Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	5112000	usd
CY2022Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	5532000	usd
CY2023Q4	tgtx	Longterm Debt Before Repayments LongtermDebtBeforeRepayments	100118000	usd
CY2022Q4	tgtx	Longterm Debt Before Repayments LongtermDebtBeforeRepayments	71135000	usd
CY2023	us-gaap	Debt Instrument Repaid Principal DebtInstrumentRepaidPrincipal	0	usd
CY2022	us-gaap	Debt Instrument Repaid Principal DebtInstrumentRepaidPrincipal	0	usd
CY2023Q4	us-gaap	Loans Payable LoansPayable	100118000	usd
CY2022Q4	us-gaap	Loans Payable LoansPayable	71135000	usd
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent	-0	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	-0	usd
CY2023Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	100118000	usd
CY2022Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	71135000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	2200000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	2700000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	2200000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1446000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1581000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9231000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10344000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	10677000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	11925000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2388000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2100000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2080000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1913000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1827000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	4715000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	15023000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4346000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	10677000	usd
CY2019Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1025	pure
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	418300000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	400400000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	316962000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	303729000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	45806000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	42031000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	12275000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	10325000	usd
CY2023Q4	tgtx	Deferred Tax Asset Disallowed Interest DeferredTaxAssetDisallowedInterest	3328000	usd
CY2022Q4	tgtx	Deferred Tax Asset Disallowed Interest DeferredTaxAssetDisallowedInterest	3882000	usd
CY2023Q4	tgtx	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	36613000	usd
CY2022Q4	tgtx	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	39411000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3333000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	985000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	418317000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	400363000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	418317000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	400363000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	400000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	13062000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-198335000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-348101000	usd
CY2023	tgtx	Income Tax Expense Benefit Expected IncomeTaxExpenseBenefitExpected	2743000	usd
CY2022	tgtx	Income Tax Expense Benefit Expected IncomeTaxExpenseBenefitExpected	-41650000	usd
CY2021	tgtx	Income Tax Expense Benefit Expected IncomeTaxExpenseBenefitExpected	-73101000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	111000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-7242000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-3445000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-3430000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-6389000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-8337000	usd
CY2023	tgtx	Effective Income Tax Rate Reconciliation Officer Compensation Limitation EffectiveIncomeTaxRateReconciliationOfficerCompensationLimitation	1167000	usd
CY2022	tgtx	Effective Income Tax Rate Reconciliation Officer Compensation Limitation EffectiveIncomeTaxRateReconciliationOfficerCompensationLimitation	4391000	usd
CY2021	tgtx	Effective Income Tax Rate Reconciliation Officer Compensation Limitation EffectiveIncomeTaxRateReconciliationOfficerCompensationLimitation	439000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-179000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	374000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	428000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-12445000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	17599000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-6726000	usd
CY2023	tgtx	Effective Income Tax Rate Reconciliation Change In State Tax Rates Amount EffectiveIncomeTaxRateReconciliationChangeInStateTaxRatesAmount	-5531000	usd
CY2022	tgtx	Effective Income Tax Rate Reconciliation Change In State Tax Rates Amount EffectiveIncomeTaxRateReconciliationChangeInStateTaxRatesAmount	0	usd
CY2021	tgtx	Effective Income Tax Rate Reconciliation Change In State Tax Rates Amount EffectiveIncomeTaxRateReconciliationChangeInStateTaxRatesAmount	0	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	17954000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	32917000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	90742000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	390000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	300000	usd
CY2023	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	900000	usd
CY2022	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	1300000	usd
CY2021	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	900000	usd
CY2023Q4	us-gaap	Contractual Obligation ContractualObligation	115400000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	15023000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2388000	usd
CY2023Q4	tgtx	Lessee Operating Lease Liability To Be Paid Year Two And Three LesseeOperatingLeaseLiabilityToBePaidYearTwoAndThree	4180000	usd
CY2023Q4	tgtx	Lessee Operating Lease Liability To Be Paid Year Four And Five LesseeOperatingLeaseLiabilityToBePaidYearFourAndFive	3740000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	4715000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	100403000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturing In Years Two And Three LongTermDebtMaturingInYearsTwoAndThree	100403000	usd
CY2023Q4	us-gaap	Long Term Debt Maturing In Years Four And Five LongTermDebtMaturingInYearsFourAndFive	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	0	usd
CY2023Q4	us-gaap	Contractual Obligation ContractualObligation	115426000	usd
CY2023Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	2388000	usd
CY2023Q4	us-gaap	Contractual Obligation Due In Second And Third Year ContractualObligationDueInSecondAndThirdYear	104583000	usd
CY2023Q4	us-gaap	Contractual Obligation Due In Fourth And Fifth Year ContractualObligationDueInFourthAndFifthYear	3740000	usd
CY2023Q4	us-gaap	Contractual Obligation Due After Fifth Year ContractualObligationDueAfterFifthYear	4715000	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	2200000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	2700000	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	2200000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	15000000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001437749-24-006144-index-headers.html	Edgar Link	pending
0001437749-24-006144-index.html	Edgar Link	pending
0001437749-24-006144.txt	Edgar Link	pending
0001437749-24-006144-xbrl.zip	Edgar Link	pending
ex_579420.htm	Edgar Link	pending
ex_579421.htm	Edgar Link	pending
ex_579423.htm	Edgar Link	pending
ex_579424.htm	Edgar Link	pending
ex_579425.htm	Edgar Link	pending
ex_579426.htm	Edgar Link	pending
ex_631839.htm	Edgar Link	pending
ex_632901.htm	Edgar Link	pending
ex_632982.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
picture1small.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tglogo01.jpg	Edgar Link	pending
tgtx-20231231.xsd	Edgar Link	pending
tgtx20231231_10k.htm	Edgar Link	pending
tgtx-20231231_cal.xml	Edgar Link	unprocessable
tgtx-20231231_def.xml	Edgar Link	unprocessable
tgtx-20231231_lab.xml	Edgar Link	unprocessable
tgtx-20231231_pre.xml	Edgar Link	unprocessable
tgtx20231231_10k_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TGTX
TG THERAPEUTICS, INC. Stock $tgtx

2024 Q1 Form 10-K Financial Statement

#000143774924006144 Filed on February 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TGTX TG THERAPEUTICS, INC. Stock $tgtx

2024 Q1 Form 10-K Financial Statement

#000143774924006144 Filed on February 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TGTX
TG THERAPEUTICS, INC. Stock $tgtx